ARECOR THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 136.5 GBX | 0.00% |
|
+3.02% | -25.21% |
| Apr. 23 | Arecor chief financial officer to leave in July after five years | AN |
| Apr. 23 | Arecor Therapeutics CFO to Leave in July | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 111.3 | 73.48 | 41.81 | 41.81 | - |
| Enterprise Value (EV) 1 | 93.02 | 60.68 | 35.64 | 39.73 | 41.91 |
| P/E ratio | -14.8 x | -7.5 x | -5.69 x | -6.35 x | -15.2 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 96.1 x | 30.6 x | 8.34 x | 5.51 x | 3.36 x |
| EV / Revenue | 80.3 x | 25.3 x | 7.11 x | 5.24 x | 3.36 x |
| EV / EBITDA | -14.8 x | -5.9 x | -4.99 x | -7.17 x | -17.7 x |
| EV / FCF | - | -5.48 x | -5.77 x | -10.8 x | - |
| FCF Yield | - | -18.3% | -17.3% | -9.24% | - |
| Price to Book | - | 4.21 x | 3.66 x | 5.37 x | - |
| Nbr of stocks (in thousands) | 27,835 | 30,618 | 30,627 | 30,627 | - |
| Reference price 2 | 4.000 | 2.400 | 1.365 | 1.365 | 1.365 |
| Announcement Date | 4/25/22 | 4/20/23 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 1.158 | 2.403 | 5.01 | 7.582 | 12.46 |
| EBITDA 1 | - | -6.268 | -10.29 | -7.146 | -5.539 | -2.37 |
| EBIT 1 | - | -6.439 | -10.63 | -8.181 | -6.679 | - |
| Operating Margin | - | -556.04% | -442.36% | -163.28% | -88.09% | - |
| Earnings before Tax (EBT) 1 | - | -6.945 | -10.54 | -7.813 | -6.696 | -3.29 |
| Net income 1 | -2.752 | -6.169 | -9.26 | -6.904 | -6 | -2.63 |
| Net margin | - | -532.73% | -385.35% | -137.81% | -79.13% | -21.11% |
| EPS 2 | -1.020 | -0.2700 | -0.3200 | -0.2400 | -0.2150 | -0.0900 |
| Free Cash Flow 1 | - | - | -11.08 | -6.171 | -3.67 | - |
| FCF margin | - | - | -461.05% | -123.16% | -48.4% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 7/1/21 | 4/25/22 | 4/20/23 | - | - | - |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 0.1 |
| Net Cash position 1 | - | 18.3 | 12.8 | 6.17 | 2.08 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.0422 x |
| Free Cash Flow 1 | - | - | -11.1 | -6.17 | -3.67 | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 0.5700 | 0.3700 | 0.2500 | - |
| Cash Flow per Share 2 | - | -0.2400 | -0.3700 | -0.2100 | -0.1200 | -0.0800 |
| Capex 1 | - | 0.07 | 0.3 | 0.21 | 0.22 | 0.2 |
| Capex / Sales | - | 5.96% | 12.44% | 4.19% | 2.95% | 1.61% |
| Announcement Date | 7/1/21 | 4/25/22 | 4/20/23 | - | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.365
GBP
Average target price
4.71
GBP
Spread / Average Target
+245.05%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -27.05% | 52.07M | |
| +2.48% | 42.75B | |
| +47.64% | 41.61B | |
| +12.02% | 41.34B | |
| -12.36% | 26.59B | |
| +8.42% | 25.49B | |
| -23.35% | 18.12B | |
| +30.52% | 12.24B | |
| -1.77% | 11.76B | |
| +7.86% | 11B |
- Stock Market
- Equities
- AREC Stock
- Financials Arecor Therapeutics plc
